Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dare Bioscience, Inc.CERU · Entity 7799 | CFO | January 05, 2017 | January 09, 2017 |
| Disc Medicine, Inc.GMTX · Entity 2273 | Chief Financial Officer | February 05, 2021 | February 10, 2021 |
| SYNLOGIC, INC.SYBX · Entity 7801 | See Remarks | December 06, 2021 | February 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dare Bioscience, Inc.
Report date January 05, 2017 · Filed January 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2027-01-04 | Direct | 50,000 |
Reported balance
After 2017-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-05 · Grant · Acquired 50,000 · Balance 50,000 F1: This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019.
Disc Medicine, Inc.
Report date February 05, 2021 · Filed February 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.62 · Expires 2030-10-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-02-05 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Stock option to purchase common stock issued as merger consideration pursuant to the Agreement and Plan of Merger by and among Gemini Therapeutics Inc., FS Development Corp., FSG Merger Sub Inc. and Shareholder Representative Services LLC, dated as of October 15, 2020 (the "Merger Agreement"). This option shall vest and become exercisable in monthly installments over a period of 24 months from the Vesting Start Date, April 17, 2020, provided that as of each such vesting date the Grantee remains in a business relationship with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option to purchase common stock issued as merger consideration pursuant to the Agreement and Plan of Merger by and among Gemini Therapeutics Inc., FS Development Corp., FSG Merger Sub Inc. and Shareholder Representative Services LLC, dated as of October 15, 2020 (the "Merger Agreement"). This option shall vest and become exercisable in monthly installments over a period of 24 months from the Vesting Start Date, April 17, 2020, provided that as of each such vesting date the Grantee remains in a business relationship with the Company.
SYNLOGIC, INC.
Report date December 06, 2021 · Filed February 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2031-12-06 | Direct | 50,000 |
Reported balance
After 2021-12-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-06 · Grant · Acquired 50,000 · Balance 50,000 F1: The options were issued to the Reporting Person pursuant to the Issuer's 2015 Equity Incentive Award Plan. Such options vest in 12 equal monthly installments starting November 1, 2021, provided the Reporting Person continues to provide services to the Issuer. An aggregate of 50% of the options shall vest immediately if the Issuer terminates the Reporting Person's services before May 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were issued to the Reporting Person pursuant to the Issuer's 2015 Equity Incentive Award Plan. Such options vest in 12 equal monthly installments starting November 1, 2021, provided the Reporting Person continues to provide services to the Issuer. An aggregate of 50% of the options shall vest immediately if the Issuer terminates the Reporting Person's services before May 1, 2022.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Pandion Therapeutics, Inc.
Report date April 01, 2021 · Filed April 01, 2021
Section 16 reporting ended · disclosed 2021-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Danforth Advisors, LLC | 0 |
Reported balance
After 2021-04-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-04-01 · Other · Disposed 13,196 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 06, 2021 Filed Feb 1, 2022 16:05 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0000899243-22-003838 · doc4.xml · derivative · entry 1 BELOFF GREGG · CIK 0001171002 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-12-06 F1 · derivative.exercise_date: The options were issued to the Reporting Person pursuant to the Issuer's 2015 Equity Incentive Award Plan. Such options vest in 12 equal monthly installments starting November 1, 2021, provided the Reporting Person continues to provide services to the Issuer. An aggregate of 50% of the options shall vest immediately if the Issuer terminates the Reporting Person's services before May 1, 2022. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 19:53 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | OtherCommon Stock | 13,196 | $60.00 | $791,760.00 |
DisclosureSEC source: 0000899243-21-014456 · doc4.xml · nonDerivative · entry 1 BELOFF GREGG · CIK 0001171002 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By Danforth Advisors, LLC Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. Read SEC document |
| October 23, 2019 Filed Oct 24, 2019 19:12 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0000899243-19-025927 · doc4.xml · derivative · entry 1 BELOFF GREGG · CIK 0001171002 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-10-23 F1 · derivative.exercise_date: The option vest with respect to 25% of the shares on a date that is 6 months from the date of grant, with the remaining shares to vest in equal monthly installments over the following 18 months, subject to the Reporting Person continuing to provide services to the Issuer as Interim Chief Financial Officer through each such vesting date. Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 17:08 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-002970 · doc4.xml · derivative · entry 1 BELOFF GREGG · CIK 0001171002 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-01-04 F1 · derivative.exercise_date: This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.